Prevalence and Risk Factors for Sexually Transmitted Infections in Gay and Bisexual Prostate Cancer Survivors: Results From the Restore-2 Study

Christopher W. Wheldon¹, Elizabeth Polter², B. R. Simon Rosser², Alex J. Bates², Ryan Haggart², Morgan Wright², Darryl Mitteldorf⁴, Michael W. Ross⁵, Badrinath R. Konety⁶, Nidhi Kohli⁷, Kristine M. C. Talley⁸, William West⁹ and Alexander K. Tatum¹⁰

¹ Cancer Health Equity, Education and Research Lab, Department of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, PA, United States, ² Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, United States, ³ Department of Urology, University of Minnesota, Minneapolis, MN, United States, ⁴ Malecare Cancer Support, New York, NY, United States, ⁵ Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, MN, United States, ⁶ Department of Urology, Rush Medical College, Chicago, IL, United States, ⁷ Department of Educational Psychology, University of Minnesota, Minneapolis, MN, United States, ⁸ Adult and Geriatric Health, University of Minnesota School of Nursing, Minneapolis, MN, United States, ⁹ Department of Writing Studies, University of Minnesota, Minneapolis, MN, United States, ¹⁰ Department of Counseling Psychology, Social Psychology, and Counseling, College of Health, Ball State University, Muncie, IN, United States

Background: Equitable cancer survivorship care for gay and bisexual male (GBM) prostate cancer survivors should be responsive to their sexual health needs. Rates of sexually transmitted infections (STIs) are higher among GBM compared to heterosexual men across the lifespan. In addition, evidence suggests that GBM will use a variety of strategies to cope with sexual dysfunction that may increase risk for STIs. The purpose of this study was to determine the prevalence of STIs following prostate cancer treatment among GBM and identify risk factors.

Methods: In 2019, 401 GBM previously treated for prostate cancer were recruited into the Restore-2 Study. They completed a baseline online questionnaire with items assessing STIs diagnosed since being treated for prostate cancer. Any STI diagnoses was regressed on demographic, clinical, and relationship related variables using binary logistic regression.

Results: Forty-five participants (11.4%) were diagnosed with an STI during or following their prostate cancer treatment. The mostly commonly diagnosed STI was syphilis (4.3%), followed by gonorrhoea (2.8%), and chlamydia (2.5%). Four participants were infected with HIV following their prostate cancer treatment. Independent risk factors for STI diagnosis included time since prostate cancer diagnosis (aOR = 1.18; 95% CI: 1.10-1.26), nonmonogamous sexual relationship (aOR = 11.23; 95% CI: 2.11-59.73), better sexual function (aOR = 1.02; 95% CI: 1.01-1.04), penile injection treatment (aOR = 3.28; 95% CI: 1.48-7.29), and multiple sex partners (aOR = 5.57; 95% CI: 1.64-18.96).
**INTRODUCTION**

Equitable cancer care for gay and bisexual men (GBM) with prostate cancer should be responsive to their specific sexual health needs. Prostate cancer treatments are known to adversely impact sexual functioning among men in the general population as well as among GBM (1–3). Psychosocial interventions to treat sexual dysfunction following treatment are largely designed for prostate cancer survivors who are in monogamous heterosexual relationships (4, 5). Thus, these approaches are not responsive to the experiences, specific needs, or health risks disproportionately affecting GBM. As a population, older GBM differ from older heterosexual men in ways that may have a significant impact on their sexual rehabilitation needs.

Anal intercourse is a common and culturally important sexual behavior for GBM across the lifecourse (6). Older GBM are also more likely to be single or in consensually nonmonogamous relationships compared to their heterosexual peers (7, 8). Some evidence suggests that GBM will use a variety of strategies to cope with sexual dysfunction following prostate cancer treatment, including changing roles in sex (e.g., from the insertive to receptive anal sex) and opening up previously monogamous relationships to other partners (5). Both coping strategies can increase risk for STIs. In addition, late and long-term effects of prostate cancer treatment, such as chronic radiation proctitis and inflammation, may increase the risk of sexually transmitted infections (STIs) for GBM engaging in receptive anal sex (9). Rates of STIs are higher among GBM at all ages compared to heterosexual men (10, 11); however, the prevalence and predictors of STIs among older GBM cancer survivors who have experienced sexual dysfunction has not been previously studied.

The purpose of this study was to determine the prevalence of STIs following prostate cancer treatment among GBM and to identify risk factors. We hypothesized that the following variables would be positively associated with a post-prostate cancer treatment STI diagnosis: (1) nonmonogamy in the primary relationship; (2) change to an anal receptive sex role; and (3) radiation treatment compared to surgery alone. We also explored the association of sociodemographic, clinical, and behavioral variables with STI diagnosis.

**MEASURES**

**Sexually Transmitted Infections**

Participants were asked to indicate if they ever had the following sexually transmitted infections “diagnosed before prostate cancer treatment” or “diagnosed after prostate cancer treatment”: HIV (or AIDS), syphilis, gonorrhea, chlamydia, HPV (genital or anal warts), herpes simplex virus (HSV), hepatitis A, hepatitis B, or hepatitis C. They could answer yes separately for each time point (i.e., before or after prostate cancer treatment). One participant who selected that they were diagnosed with HIV (N=1) both before and after prostate cancer were counted among participants diagnosed with HIV before, but not after prostate cancer. Participants who reported that they were diagnosed with syphilis (N=2), chlamydia (N=2), or HPV (N=1) both before and after cancer were counted in both categories. For the remaining STIs, no participant listed a diagnosis both before and after prostate cancer treatment. Two composite variables were created to indicate any of the nine STIs before or after prostate cancer treatment, respectively.

**Sociodemographic Variables**

Demographic questions were adapted from the U.S. Census and from the 2018 American Community Survey and included age, race/ethnicity, U.S. region, and educational attainment.

**Clinical Variables**

Prostate cancer treatment type was investigated by asking participants to check which treatments they had undergone in...
nine categories, which at analysis were collapsed into: surgery or cryotherapy only, radiation only, hormone therapy (in combination with surgery and/or radiation), and other. Time since prostate cancer diagnosis was calculated in years.

**Relationship Characteristics**
Current relationship status (single, dating, married or in a long-term relationship, or widowed, divorced no longer in a relationship) was assessed with two items. The first asked What is your current relationship status? Responses were combined into a dichotomous variable to contrast participants who were married or in a long-term relationship with those who were single, dating, widowed, divorced or no longer in a relationship. If the response was married or in a long-term relationship with a man, a follow-up question (How many years have you been in a relationship with this man)? was used to document years in current relationship with a man. Five participants who were in a relationship with a woman were not asked this follow-up question. A participant was considered to be in a non-monogamous relationship if they were married, or in a long-term relationship and reported either (1) one sexual partner who was not their primary partner in the past month or (2) two or more sexual partners in the past month.

**Disease Specific Quality of Life and Sexual Function**
The Expanded Prostate Cancer Index Composite (EPIC-50) measures for the frequency and perceived bother of bowel and sexual symptoms were included. The subscale reliability (r=0.80) and internal consistency were adequate (α≥ 0.82) (13). All scales total 100, with higher scores indicating better functioning or less bother. To assess treatments used for sexual function, participants were provided with a list of treatment options (e.g., Viagra, Cialis, or other erectile enhancing drugs; vacuum pump to help with erections; and Penile injections (e.g., Coverjet)) and asked which of the following they tried in the last 90 days. They could select more than one treatment. For this analysis, they were classified as having used the treatment if they reported using it at least once in the previous 90 days.

**Behavioral Risk Factors**
Risky alcohol use was measured with two items that asked (1) how often a participant had a drink containing alcohol (e.g., a 12 ounce can or glass of beer or cooler, a 5-ounce glass of wine, or a drink containing 1 shot of liquor and (2) how many alcoholic drinks a participant had on a typical day when drinking alcohol. Participants were classified as having risky alcohol use if they indicated more than five drinks on any day in the previous year or more than 5 drinks per day on a typical day when drinking (14). Change in sex role was assessed in an item asking how often they had changed their sex role (from "top" to "bottom") to help with the sexual effects of prostate cancer treatment in the past ninety days. Participants were classified as changing their role in sex if they reported a change in role at least once in the previous 90 days. Participants were asked "in the last three months, with how many men (including your partner or spouse, if applicable) have you engaged in any kind of sex? (0, 1, or more than 1).

**Data Analysis**
Frequencies and percentages were calculated for the prevalence of each STI after prostate cancer treatment. Variables including demographics, prostate cancer treatment and time since diagnosis, relationship variables, disease-specific quality-of-life, use of therapies for erectile function, and behavioral risk variables, were calculated for participants with and without a post-prostate cancer STI diagnosis using means and standard deviations (for continuous variables) and frequencies and percentages (for categorical variables). Logistic regression was used to calculate the association of post-prostate cancer STI with each characteristic. A multivariable model was used to identify the strongest independent correlates of STI diagnosis. All hypothesis tests were two-sided, with significance level of p ≤ 0.05. Sample size estimates were based on the parent study (12). All analyses were conducted in Stata version 16 (StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC).

**RESULTS**
The characteristics of the sample are described in Table 1. The sample was primarily non-Hispanic White (87.6%) with an average age of 63.5 (SD=6.7). Prostate cancer treatment was primarily surgery (58.2%) with an average of 5.3 (SD=4.9) years since diagnosis. Most (62.1%) had used an erectile enhancing drug to treat sexual dysfunction. Approximately half were married or in a long-term relationship with a man (49.0%) and most reported a lifetime STI prior to their cancer diagnosis (55.7%).

Forty-five participants (11.4%) answered that they had been diagnosed with an STI following their prostate cancer treatment (Table 2). The mostly commonly diagnosed STI was syphilis (4.3%), followed by gonorrhoea (2.8%), and chlamydia (2.5%). Four participants (1.0%) were infected with HIV following their prostate cancer treatment.

Independent risk factors for STI diagnosis (Table 1) included time since prostate cancer diagnosis (aOR = 1.18; 95% CI: 1.10-1.26), nonmonogamous sexual relationship (aOR = 11.23; 95% CI: 2.11-59.73), better sexual function (aOR = 3.28; 95% CI: 1.26), nonmonogamous sexual relationship (aOR = 5.57; 95% CI: 1.01-1.04), penile injection treatment (aOR = 3.28; 95% CI: 1.48-7.29), and multiple sex partners (aOR = 5.57; 95% CI: 1.64-18.96).

**DISCUSSION**
The acquisition of STIs among GBM prostate cancer survivors is an area that has received almost no attention in the clinical literature. STIs among adults older than age 50 are relatively uncommon in the general population, but GBM remain at risk of acquiring new infections into late adulthood (11, 15). Our findings confirm that GBM prostate cancer survivors with treatment-related sexual dysfunction are still at high-risk for STIs. Approximately 1 in 9 of the survivors in this study reported...
### TABLE 1 | Correlates of acquiring sexually transmitted infection (STI) post prostate cancer treatment among gay and bisexual men (N = 395).

| Sociodemographic variables |  |  |  |  |  |  |  |
|----------------------------|---|---|---|---|---|---|---|
| Age, mean (SD) | 63.5 (6.7) | 63.5 (6.6) | 63.2 (6.7) | 0.99 (0.95-1.04) | 0.74 | 0.97 (0.91-1.02) | 0.25 |
| Race/Ethnicity | 346 (87.6%) | 305 (87.1%) | 41 (91.1%) | 0.66 (0.23-1.93) | 0.45 | 0.65 (0.20-2.11) | 0.48 |
| Region | 107 (27.1%) | 94 (26.9%) | 13 (28.9%) | 0.97 (0.91-1.02) | 0.25 |
| United States West | 127 (32.2%) | 109 (31.1%) | 18 (40.0%) | 1.19 (0.56-2.57) | 0.65 | 1.81 (0.76-4.31) | 0.18 |
| United States South | 74 (18.7%) | 70 (20.0%) | 4 (8.9%) | 0.41 (0.13-1.32) | 0.14 | 0.73 (0.21-2.56) | 0.63 |
| United States Northeast | 87 (22.0%) | 77 (22.0%) | 10 (22.2%) | 0.94 (0.39-2.26) | 0.88 | 1.24 (0.46-3.32) | 0.67 |
| Education | 92 (23.3%) | 83 (23.7%) | 9 (20.0%) | 0.95 (0.40-2.23) | 0.90 | 1.07 (0.41-2.78) | 0.88 |
| Clinical variables |  |  |  |  |  |  |  |
| Treatment type | 230 (58.2%) | 203 (58.0%) | 27 (60.0%) | 1.00 | 1.00 |
| Radiation alone (external or brachytherapy) | 74 (18.7%) | 64 (18.3%) | 10 (22.2%) | 1.17 (0.54-2.56) | 0.69 | 1.39 (0.57-3.38) | 0.47 |
| Disease specific quality of life and sexual function |  |  |  |  |  |  |  |
| EPIC Sexual Function | 35.5 (21.2) | 34.6 (21.4) | 42.9 (18.5) | 1.02 (1.00-1.03) | <0.001 | 1.02 (1.01-1.04) | <0.001 |
| EPIC Sexual Bother | 39.2 (26.3) | 38.9 (26.8) | 41.8 (22.3) | 1.00 (0.99-1.02) | 0.48 | 0.99 (0.97-1.01) | 0.35 |
| Behavioral risk variables |  |  |  |  |  |  |  |
| Risky drinking: >5 drinks on any day in the past year OR >5 drinks per day on average | 97 (29.7%) | 85 (29.5%) | 12 (30.8%) | 1.06 (0.51-2.19) | 0.87 | 0.88 (0.38-2.01) | 0.76 |
| STI prior to PCa Dx | 220 (55.7%) | 197 (56.3%) | 23 (51.1%) | 0.81 (0.44-1.51) | 0.51 | 0.79 (0.39-1.60) | 0.51 |

(Continued)
acquiring an STI following their prostate cancer treatment. The most commonly acquired STI was syphilis, which reflects established trends in syphilis incidence among GBM in the U.S (16). The prevalence of syphilis among men in the current study (4.3%) was higher than the point prevalence in a recent study of GBM in North American and Europe, but still within range of estimates (3.4%; 95% CI: 1.8% to 5.4%) (17). The prevalence of syphilis among men in the current study established trends in syphilis incidence among GBM in the U.S (16). The prevalence of syphilis among men in the current study (4.3%) was higher than the point prevalence in a recent study of GBM in North American and Europe, but still within range of estimates (3.4%; 95% CI: 1.8% to 5.4%) (17).

Several behavioral and clinical correlates of STIs were identified in the current study. As hypothesized, for participants in long-term relationships, nonmonogamy was associated with increased risk of STIs. Nonmonogamous relationship agreements are common among GBM (8), particularly among older age cohorts and among those in long-term relationships of five or more years (18). Clinicians treating GBM for prostate cancer related sexual dysfunction should not make the assumption that patients who are married or with a long-term partner are monogamous (19). Taking a system-wide approach to sexual health in cancer survivorship care can help to overcome organizational and interpersonal barriers to patient-provider sexual health communication (20).

Another behavioral factor associated with STI risk was having multiple recent oral or anal sex partners; however, the hypothesis about role change in sex was not supported. In other words, we failed to find evidence that changing from an insertive (i.e., “top”) to receptive (i.e., “bottom”) role after prostate cancer treatment was associated with greater likelihood of STIs. Despite the null finding, nearly 1 in 4 participants described a change in role. These role changes may result from decreased erectile functioning following PCa treatment and highlight the importance of STI prevention in this population.

Radiation treatment was also not associated with STIs in this study. It has been hypothesized that inflammatory conditions like proctitis may increase susceptibility to STI acquisition through receptive anal sex (21). While we did not measure proctitis directly in this study, radiation proctitis is a potential long term effect of prostate cancer treatment (9). Proctitis can also result from untreated STIs (22), thus it is important for oncologists treating bowel dysfunction in GBM with prostate cancer to test for STIs. Future studies should also continue to examine the role of treatment related inflammatory bowel conditions on STI risk for those engaging in receptive anal sex.

With regard to other clinical factors, years since prostate cancer diagnosis was positively associated with STI diagnosis. This finding may reflect the timeframe used to assess STI diagnoses (i.e., since prostate cancer treatment) or time-based improvements in sexual function. Relatedly, better sexual function and use of penile injections for erectile dysfunction were both independently associated with STIs; however, other treatments for erectile dysfunction were not associated with STI risk. It is unclear why penile injections, and not oral medications (e.g., sildenafil), were associated with increases in STI acquisition. Future research should explore potential explanations such as higher efficacy of injections in producing erections rigid enough for anal intercourse, the context of use, and the potential that a wound at the injection site may increase risk for STI transmission.

It is important to note that lifetime history of STIs was not predictive of post-prostate cancer treatment STIs, suggesting that risk was not solely concentrated among men with a history of STIs. The process of sexual rehabilitation following treatment for prostate cancer may involve additional behavioral and

### Table 1 | Continued

| Type of Sexually Transmitted Infection | N  | %   |
|--------------------------------------|----|-----|
| Any                                  | 45 | 11.4|
| Syphilis                             | 17 | 4.3 |
| Gonorrhea                            | 11 | 2.8 |
| Chlamydia                            | 10 | 2.5 |
| Human papillomavirus (Genital or Anal Warts) | 9 | 2.3 |
| HIV                                  | 4  | 1   |
| Herpes Simplex Virus (HSV)           | 4  | 1   |
| Hepatitis C                          | 4  | 1.1 |
| Hepatitis B                          | 3  | 0.8 |
| Hepatitis A                          | 2  | 0.5 |

---

**TABLE 2** | Frequency of sexually transmitted infections among gay and bisexual male prostate cancer survivors since their prostate cancer treatment (N = 395).

| Type of Sexually Transmitted Infection | N  | %   |
|--------------------------------------|----|-----|
| Any                                  | 45 | 11.4|
| Syphilis                             | 17 | 4.3 |
| Gonorrhea                            | 11 | 2.8 |
| Chlamydia                            | 10 | 2.5 |
| Human papillomavirus (Genital or Anal Warts) | 9 | 2.3 |
| HIV                                  | 4  | 1   |
| Herpes Simplex Virus (HSV)           | 4  | 1   |
| Hepatitis C                          | 4  | 1.1 |
| Hepatitis B                          | 3  | 0.8 |
| Hepatitis A                          | 2  | 0.5 |

---

**TABLE 2** | Frequency of sexually transmitted infections among gay and bisexual male prostate cancer survivors since their prostate cancer treatment (N = 395).
psychosocial changes that increase STI risk. For example, men may forgo the use of condoms to help manage erectile dysfunction. Safer sex negotiations with existing and new partners may also be impacted by lowered sexual self-esteem resulting from long term sexual dysfunction. Terror management theory suggests that a mortality threat (e.g., cancer) can increase sexual risk behaviors among men (23). It is theorized that when faced with a mortality threat, men may cope by engaging in self-enhancing sexual behaviors. Further research is needed to directly test this hypothesis in cancer survivors.

There are several limitations to the research design. For many of the associations reported, the temporality relative to STI acquisition could not be established. Thus, the associations do not represent cause and effect relationships. Furthermore, the measures were self-reported with no objective verification of STI diagnoses possibly leading to underreporting. External validity is limited by the non-probability sample of mostly highly educated non-Hispanic white men. Finally, the estimated associations may be unreliable due to limited distributions in some variables resulting in wide confidence intervals. Replication of these findings on ethnoracially and socioeconomically diverse samples is essential.

Despite these limitations, this analysis has several strengths. We recently conducted a systematic review of all publications (from 1995 to 2022) on GBM prostate cancer patients in English, Spanish and French. Based on this review, we confirm this is the first study to examine the prevalence and risk factors for STIs among GBM prostate cancer survivors. The findings indicate that older GBM who have completed treatment for prostate cancer and have experienced significant sexual dysfunction are still at risk for acquiring new STIs. Cancer survivorship and sexual rehabilitation care plans for GBM following prostate cancer treatment should include STI prevention.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Institutional Review Board at the University of Minnesota. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Conceptualization, BR, KT, CW, DM, MR, BK, and NK; Methodology, BR, NK, EP, and MW; Validation, NK and EP; Formal Analysis, NK, EP, and MW; Investigation, BR, EP, MW, RH, and NK; Data Curation, RW, MW, and NK; Writing – Original Draft, BR, EP, and KT; Writing – review and editing, all authors; Supervision, BR and NK; Project administration, BR, BK, and NK; Funding acquisition, BR, KT, CW, WW, DM, MR, BK, and NK; All authors contributed to the article and approved the submitted version.

**FUNDING**

This study is supported by funding from the National Cancer Institute (NCI) [1R01CA218657; PI: Rosser]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

---

**REFERENCES**

1. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual Function and Bother After Radical Prostatectomy or Radiation for Prostate Cancer: Multivariate Quality-of-Life Analysis From Capsure. *Urology* (1999) 54:503–8. doi: 10.1016/S0090-4295(99)00172-7
2. Lassen B, Gahttinger H, Saxer S. A Systematic Review of Physical Impairments Following Radical Prostatectomy: Effect of Psychoeducational Interventions. *J Adv Nurs* (2013) 69:2602–12. doi: 10.1111/jan.12186
3. Polter EJ, Wheldon CW, Kohli N, Rosser BR. Health-Related Quality of Life by HIV Status in Gay and Bisexual Prostate Cancer Survivors: Findings From the Restore Study. *Psycho-Oncology* (2019) 28(12):2351–7. doi: 10.1002/pon.5228
4. Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, et al. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. *Vaccine* (2013) 31 (Suppl 7):H1–31. doi: 10.1016/j.vaccine.2013.10.003
5. Rosser BRS, Merengwa E, Capistrant BD, Iantaffi A, Kilian G, Kohli N, et al. Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex With Men: A Review. *LGBT Health* (2016) 3:32–41. doi: 10.1089/lgbth.2015.0092
6. Dodge B, Herbenick D, Fu TCI, Schick V, Reece M, Sanders S, et al. Sexual Behaviors of U.S. Men by Self-Identified Sexual Orientation: Results From the 2012 National Survey of Sexual Health and Behavior. *J Sexual Med* (2016) 13:637–49. doi: 10.1016/j.jsxm.2016.01.015
7. Fredriksen-Goldsen KI, Kim HJ, Shui C, Bryan AEB. Chronic Health Conditions and Key Health Indicators Among Lesbian, Gay, and Bisexual Older US Adults, 2013-2014. *Am J Public Health* (2017) 107:1332–8. doi: 10.2105/AJPH.2017.303922
8. Haupert ML, Moors AC, Gesselman AN, Garcia JR. Estimates and Correlates of Engagement in Consensually non-Monogamous Relationships. *Carr Sex Health Rep* (2017) 9:155–65. doi: 10.1007/s11930-017-0121-6
9. Vanneste BGL, Van De Voorde L, de Ridder RJ, Van Limbergen EJ, Lambin P, van Lin EN. Chronic Radiation Proctitis: Tricks to Prevent and Treat. *Int J Colorectal Dis* (2013) 30:1293–303. doi: 10.1007/s00384-015-2289-4
10. Grey JA, Bernstein KT, Sullivan PS, Kidd SE, Gift TL, Hall EW, et al. Rates of Primary and Secondary Syphilis Among White and Black Non-Hispanic Men Who Have Sex With Men, Us States, 2014. *J Acquir Immune Defic Syndr* (2018) 76(3):e65–73. doi: 10.1136/sxtrans-2017-053264.342
11. Poynten JM, Grolich AE, Templeton DJ. Sexually Transmitted Infections in Older Populations. *Carr Opin Infect Dis* (2013) 26:80–5. doi: 10.1097/QCO.0b013e32825c2173
12. Rosser BRS, Wright M, Hoefer C, Polter EJ, Haggart R, Kilian G, et al. Recruiting an Underserved, Difficult to Reach Population Into a Cancer Trial: Strategies From the Restore- 2 Rehabilitation Trial for Gay and Bisexual Prostate Cancer Patients. *Clin Trials* (2022) 1–12. doi: 10.1177/1740774221077678
13. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men With Prostate Cancer. *Urology* (2000) 56:899–905. doi: 10.1001/S0090-4295(00)00858-X
14. National Institute on Alcohol Abuse and Alcoholism (NIAAA). *Drinking Levels Defined*. Available at: https://www.niaaa.nih.gov/alcohol-health/
15. Rice CE, Vasilenko SA, Fish JN, Lanza ST. Sexual Minority Health Disparities: An Examination of Age-Related Trends Across Adulthood in a National Cross-Sectional Sample. *Ann Epidemiol* (2019) 31:20–5. doi: 10.1016/j.annepidem.2019.01.001

16. Abara WE, Hess KL, Neblett Fanfair R, Bernstein KT, Paz-Bailey G. Syphilis Trends Among Men Who Have Sex With Men in the United States and Western Europe: A Systematic Review of Trend Studies Published Between 2004 and 2015. *PloS One* (2016) 11:e0159309. doi: 10.1371/journal.pone.0159309

17. Tsuoi M, Evans J, Davies EP, Rowley J, Korenromp EL, Clayton T, et al. Prevalence of Syphilis Among Men Who Have Sex With Men: A Global Systematic Review and Meta-Analysis From 2000–20. *Lancet Global Health* (2021) 9:e1110–8. doi: 10.1016/S2214-109X(21)00221-7

18. Wheldon CW, Pathak EB. Masculinity and Relationship Agreements Among Male Same-Sex Couples. *J Sex Res* (2010) 47:460–70. doi: 10.1080/00224490903100587

19. Rosser BRS, Rider GN, Kapoor A, Talley KMC, Haggart R, Kohli N, et al. Every Urologist and Oncologist Should Know About Treating Sexual and Gender Minority Prostate Cancer Patients: Translating Research Findings Into Clinical Practice. *Transl Androl Urol* (2021) 10:3208–25. doi: 10.21037/tau-20-1052

20. Natonal LGBT Health Education Center. *Taking Routine Histories of Sexual Health: A System-Wide Approach for Health Centers*. Boston: MA (2015).

21. Ian K, Jordan A, Shannon C, Richard G, Lisa M. P064 Receptive Anal Intercourse in Patients With Inflammatory Bowel Disease: The Role of Sexually Transmitted Infections. *Off J Am Coll Gastroenterol ACG* (2019) 114:S17. doi: 10.14309/01.ajg.0000578328.00040.39

22. Steed JM, Henry-Okafor Q, Pitts CJ. Proctitis in Men Who Have Sex With Men. *Nurs Clinics North Am* (2020) 55:325–35. doi: 10.1016/j.cnur.2020.05.003

23. Lam SR, Rios Morrison K, Smeesters D. Gender, Intimacy, and Risky Sex: A Terror Management Account. *Pers Soc Psychol Bull* (2009) 35:1046–56. doi: 10.1177/0146167209336607

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Wheldon, Polter, Rosser, Bates, Haggart, Wright, Mitteldorf, Ross, Konety, Kohli, Talley, West and Tatum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*